Galanin receptor 2 utilizes distinct signaling pathways to suppress cell proliferation and induce apoptosis in HNSCC

Kanazawa,Takeharu; Misawa,Kiyoshi; Misawa,Yuki; Maruta,Mikiko; Uehara,Takayuki; Kawada,Kazumi; Nagatomo,Takafumi; Ichimura,Keiichi

doi:10.3892/mmr.2014.2362

Galanin receptor 2 utilizes distinct signaling pathways to suppress cell proliferation and induce apoptosis in HNSCC

Authors:
- Takeharu Kanazawa
- Kiyoshi Misawa
- Yuki Misawa
- Mikiko Maruta
- Takayuki Uehara
- Kazumi Kawada
- Takafumi Nagatomo
- Keiichi Ichimura
View Affiliations

Affiliations: Department of Otolaryngology‑Head and Neck Surgery, Jichi Medical University School of Medicine, Shimotsuke, Tochigi 329‑0498, Japan, Department of Otolaryngology‑Head and Neck Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431‑3192, Japan, Department of Otorhinolaryngology‑Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903‑0215, Japan
Published online on: July 4, 2014 https://doi.org/10.3892/mmr.2014.2362
Pages: 1289-1294

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Galanin and its receptors, GALR1 and GALR2, are tumor suppressors and represent therapeutic targets in head and neck squamous cell carcinoma (HNSCC). In the present study, it was demonstrated that the re‑expression of GALR1 in GALR1 and GALR2‑negative HNSCC cells suppresses tumor cell proliferation. This is mediated via extracellular‑regulated protein kinase‑1/2 (ERK1/2)‑dependent effects on the cyclin‑dependent kinase inhibitors (CKI) and cyclin D1. In combination with galanin, GALR2 also suppressed proliferation by increasing CKI and decreasing cyclin D1 levels. In contrast to GALR1, overexpression of GALR2 also induced caspase‑3‑dependent apoptosis. It was identified that in GALR2‑transfected cells, galanin induced activation of ERK1/2 and suppressed cell proliferation. Galanin stimulation also decreased the expression of cyclin D1 and induced apoptotic DNA ladder formation in GALR2‑transfected cells. Pretreatment with the ERK1/2‑specific inhibitor U0126 and pertussis toxin prevented the suppression of cyclin D1 expression, however did not affect DNA ladder formation. In conclusion, GALR2 expression in the presence of galanin exerts antitumor effects via cell cycle arrest and apoptotic pathways, and reactivation of these pathways may have therapeutic benefits in HNSCC.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
2	Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD and Murray CJ: Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC cancer. 2:372002. View Article : Google Scholar
3	DeWire SM and Violin JD: Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res. 109:205–216. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hill SJ: G-protein-coupled receptors: past, present and future. Br J Pharmacol. 147(Suppl 1): S27–S37. 2006. View Article : Google Scholar : PubMed/NCBI
5	Berger A, Santic R, Almer D, et al: Galanin and galanin receptors in human gliomas. Acta Neuropathol. 105:555–560. 2003.PubMed/NCBI
6	Berger A, Lang R, Moritz K, et al: Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. Endocrinology. 145:500–507. 2004. View Article : Google Scholar : PubMed/NCBI
7	Wittau N, Grosse R, Kalkbrenner F, Gohla A, Schultz G and Gudermann T: The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins. Oncogene. 19:4199–4209. 2000. View Article : Google Scholar : PubMed/NCBI
8	Kanazawa T, Iwashita T, Kommareddi P, et al: Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene. 26:5762–5771. 2007. View Article : Google Scholar
9	Seufferlein T and Rozengurt E: Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res. 56:5758–5764. 1996.PubMed/NCBI
10	Iishi H, Tatsuta M, Baba M, et al: Inhibition by galanin of experimental carcinogenesis induced by azaserine in rat pancreas. Int J Cancer. 75:396–399. 1998. View Article : Google Scholar : PubMed/NCBI
11	Misawa Y, Misawa K, Kanazawa T, et al: Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer. Cancer. 120:205–213. 2014. View Article : Google Scholar : PubMed/NCBI
12	Kanazawa T, Kommareddi PK, Iwashita T, et al: Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells. Clin Cancer Res. 15:2222–2230. 2009. View Article : Google Scholar : PubMed/NCBI
13	Kanazawa T, Misawa K and Carey TE: Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma. Expert Opin Ther Targets. 14:289–302. 2010. View Article : Google Scholar : PubMed/NCBI
14	Misawa K, Kanazawa T, Misawa Y, et al: Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer. Transl Oncol. 6:338–346. 2013. View Article : Google Scholar : PubMed/NCBI
15	Misawa K, Ueda Y, Kanazawa T, et al: Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res. 14:7604–7613. 2008. View Article : Google Scholar : PubMed/NCBI
16	Henson BS, Neubig RR, Jang I, et al: Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem. 280:22564–22571. 2005. View Article : Google Scholar : PubMed/NCBI
17	Tofighi R, Joseph B, Xia S, et al: Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2). Proc Natl Acad Sci USA. 105:2717–2722. 2008. View Article : Google Scholar : PubMed/NCBI
18	Uehara T, Kanazawa T, Mizukami H, et al: Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells. Cancer Sci. Oct 30–2013.(Epub ahead of print).
19	Lang R, Gundlach AL and Kofler B: The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther. 115:177–207. 2007. View Article : Google Scholar : PubMed/NCBI
20	Fathi Z, Cunningham AM, Iben LG, et al: Cloning, pharmacological characterization and distribution of a novel galanin receptor. Brain Res Mol Brain Bres. 51:49–59. 1997. View Article : Google Scholar : PubMed/NCBI
21	Smith KE, Forray C, Walker MW, et al: Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J Biol Chem. 272:24612–24616. 1997. View Article : Google Scholar : PubMed/NCBI
22	Wang S, Clemmons A, Strader C and Bayne M: Evidence for hydrophobic interaction between galanin and the GalR1 galanin receptor and GalR1-mediated ligand internalization: fluorescent probing with a fluorescein-galanin. Biochemistry. 37:9528–9535. 1998. View Article : Google Scholar
23	Fathi Z, Battaglino PM, Iben LG, et al: Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor. Brain Res Mole Brain Res. 58:156–169. 1998. View Article : Google Scholar
24	Wang S, Hashemi T, He C, Strader C and Bayne M: Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol Pharmacol. 52:337–343. 1997.PubMed/NCBI
25	Hagemeister AL, Kittilson JD, Bergan HE and Sheridan MA: Rainbow trout somatostatin receptor subtypes SSTR1A, SSTR1B, and SSTR2 differentially activate the extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling pathways in transfected cells. J Mol Endocrinol. 45:317–327. 2010. View Article : Google Scholar
26	War SA and Kumar U: Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis. J Mol Signal. 7:52012. View Article : Google Scholar : PubMed/NCBI